HALOZYME THERAPEUTICS, INC. - Common Stock (HALO)

Q1 2019 13F Holders as of 31 Mar 2019

Type / Class
Equity / Common Stock
Shares outstanding
123,650,000
Total 13F shares
118,387,949
Share change
-59,923
Total reported value
$1,906,096,918
Put/Call ratio
34%
Price per share
$16.10
Number of holders
193
Value change
-$285,197
Number of buys
83
Number of sells
74

Institutional Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q1 2019

As of 31 Mar 2019, HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) was held by 193 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 118,387,949 shares. The largest 10 holders included Third Security, LLC, VANGUARD GROUP INC, BlackRock Inc., BB BIOTECH AG, IRIDIAN ASSET MANAGEMENT LLC/CT, JPMORGAN CHASE & CO, Invesco Ltd., STATE STREET CORP, PICTET ASSET MANAGEMENT LTD, and Thrivent Financial for Lutherans. This page lists 195 institutional shareholders reporting positions in this security for the Q1 2019 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.